Novartis selling diagnostics unit to Grifols SA

GENEVA — The pharmaceutical company Novartis said Monday that it is selling part of its diagnostics business to the Spanish company Grifols for $1.68 billion.

The company, based in Basel, Switzerland, said the deal with Grifols SA, which is based in Barcelona and is the world’s third-largest producer of plasma-derived therapies, requires regulatory approvals but is expected to be completed in the first half of 2014.


Joseph Jimenez, chief executive of Novartis, said in a statement that the sale of the company’s blood transfusion diagnostics unit ‘‘enables us to focus more sharply on our strategic businesses while providing Grifols with a platform for global expansion.’’

Novartis AG said the unit, which it acquired in 2006 as part of Chiron, an Emeryville, Calif., biotech company, had sales of $565 million in 2012.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

Novartis has its global research headquarters in Cambridge, Mass.

Associated Press

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of